RESVERATROLNING ALLOKSAN BILAN INDUKTSIYALANGAN DIABETIK KALAMUSHLARDA QON BIOKIMYOVIY KO‘RSATKICHLARIGA TA’SIRI
##submission.downloads##
Qandli diabet – bu qondagi glyukoza miqdorining ortishi bilan tavsiflanadigan surunkali metabolik kasallik bo‘lib, u ko‘plab
fiziologik va biokimyoviy o‘zgarishlarga olib keladi. Diabet paytida gematologik va biokimyoviy ko‘rsatkichlarda sezilarli
og‘ishlar kuzatiladi. So‘nggi yillarda tabiiy polifenol birikma – resveratrolning diabet patogeneziga ta’siri keng o‘rganilmoqda.
1. American Diabetes Association. (2023). *Diagnosis and classification of diabetes mellitus.* Diabetes Care, 46(Suppl
1):S19–S27.
2. DeFronzo, R. A. (2009). *From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2
diabetes mellitus.* Diabetes, 58(4), 773–795.
3. Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). *Pathophysiology and treatment of type 2 diabetes: perspectives
on the past, present, and future.* Lancet, 383(9922), 1068–1083.
4. Forbes, J. M., & Cooper, M. E. (2013). *Mechanisms of diabetic complications.* Physiological Reviews, 93(1), 137–
188.
5. International Diabetes Federation. (2021). *IDF Diabetes Atlas* (10th ed.). Brussels, Belgium.
6. Saeedi, P., et al. (2019). *Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and
2045.* Diabetes Research and Clinical Practice, 157, 107843.
7. WHO. (2022). *Global report on diabetes.* Geneva: World Health Organization.
8. Evans, J. L., et al. (2002). *Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2
diabetes.* Endocrine Reviews, 23(5), 599–622.
9. Robertson, R. P. (2004). *Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta
cells in diabetes.* Journal of Biological Chemistry, 279(41), 42351–42354.
10. Bailey, C. J., & Day, C. (2004). *Metformin: its botanical background.* Practical Diabetes International, 21(3), 115–
117.
11. Nathan, D. M. (2015). *Diabetes: advances in diagnosis and treatment.* JAMA, 314(10), 1052–1062.
12. Ramkumar, K. M., et al. (2011). *Natural products and their anti-diabetic potential.* Planta Medica, 77(14), 1686–
1697.
13. Takaoka, M. (1940). *Resveratrol, a new phenolic compound from Veratrum grandiflorum.* Journal of the Chemical
Society of Japan, 61, 365–370.
14. Baur, J. A., & Sinclair, D. A. (2006). *Therapeutic potential of resveratrol: the in vivo evidence.* Nature Reviews
Drug Discovery, 5(6), 493–506.
15. Um, J. H., et al. (2010). *AMP-activated protein kinase–deficient mice are resistant to the metabolic effects of
resveratrol.* Diabetes, 59(3), 554–563.
16. Su, H. C., et al. (2020). *Resveratrol alleviates oxidative stress and improves insulin sensitivity in diabetic rats via
SIRT1/AMPK pathway.* Molecular Medicine Reports, 22(4), 2741–2749.
17. Szkudelski, T. (2006). *Resveratrol inhibits insulin secretion from rat pancreatic islets through a mechanism involving
nitric oxide and cyclic GMP.* British Journal of Pharmacology, 149(4), 431–435.
18. Захарова С.М. Медико-социальное обоснование первичной профилактики сахарного диабета типа 2:
автореферат дис. на соиск. учен.степ. доктора мед. наук. 2005, - 48 с.
Mulkiiyat (c) 2025 «O‘zMU XABARLARI»
Ushbu ish quyidagi litsenziya asosida ruxsatlangan Kreativ Commons Attribution-NonCommercial-ShareAlike 4.0 International litsenziyasi asosida bu ish ruxsatlangan..
.jpg)
.png)
